BN Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Brookfield Corp is not a strong buy right now for a beginner long-term investor with $50,000-$100,000 to deploy. The stock has solid fundamentals and favorable analyst coverage, but the current setup is mixed: price is near short-term resistance, options sentiment is bearish-to-neutral, and there is no fresh catalyst from news or insider/congress activity. For an impatient buyer, this is a hold rather than an immediate buy.
BN is in a constructive uptrend technically, with bullish moving averages (SMA_5 > SMA_20 > SMA_200) and a positive, expanding MACD histogram. RSI_6 at 68.63 is near overbought but still not an extreme warning. Price at 46.39 is sitting just below first resistance at 46.656, with support at 45.073 and deeper support at 43.489. This suggests the stock is extended enough that upside from here may be limited in the near term, especially with the stock trend model pointing to a negative drift over the next day, week, and month.
["Q4 2025 revenue rose 3.76% YoY to 20.156B, showing steady top-line growth.", "Net income jumped 79.03% YoY and EPS rose 87.50% YoY in the latest quarter, showing strong bottom-line momentum.", "Analysts remain constructive overall, with Morgan Stanley at Overweight and a recent price target increase to $61.", "Scotiabank keeps Outperform and said the selloff looks overdone, implying value support.", "Technical trend remains bullish with moving averages aligned upward and MACD positive."]
["No news in the recent week, so there is no fresh event-driven catalyst.", "Options positioning is cautious, with put-call ratios above 1.0.", "The stock is trading close to resistance at 46.656, limiting immediate upside.", "RSI is elevated near 69, suggesting the move is somewhat stretched.", "Hedge funds and insiders are neutral with no significant recent buying trends.", "No recent congress trading data or influential figure activity was reported.", "Pattern-based trend expectation points to downside probability over the next day, week, and month."]
In Q4 2025, Brookfield delivered solid growth: revenue increased 3.76% year over year to 20.156B, net income increased 79.03% to 700M, and EPS increased 87.50% to 0.30. Gross margin slipped slightly to 25.7%, but overall the latest quarter shows improving earnings power and healthy operating momentum.
Wall Street remains positive overall. Morgan Stanley raised its price target from $60 to $61 and kept an Overweight rating. Earlier, Morgan Stanley had already moved from $58 to $60. Scotiabank lowered its target from $52 to $48.50 but maintained Outperform, saying concerns around software, AI, and private credit have pressured the group and that the selloff looks overdone. Net takeaway: analysts still favor the stock, but target changes show some caution around the sector.
